Results 291 to 300 of about 275,317 (361)

Control of post-transplant lymphoproliferative disorders and Kaposi's sarcoma by modulation of immunosuppression [PDF]

, 1987
Breinig, MK, Demetris, AJ, Griffith, BP, Ho, M, Iwatsuki, S, Jaffe, R, Makowka, L, Nalesnik, M, Starzl, TE, Steiber, A, Tzakis, A   +10 more
core  

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, EarlyView.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Long-term cancer risk after kidney transplantation: a German primary care cohort study. [PDF]

Br J Cancer
Kostev K, Schmidt BM, Tian Z.
europepmc   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

First Report of Hematopoietic Stem Cell Transplantation for Children Diagnosed with Wiskott-Aldrich Syndrome in Vietnam. [PDF]

J Blood Med
Nguyen-Ngoc-Quynh L, Nguyen-Thanh B, Nguyen ATV, Dang-Thi H, Ha-Phuong A, Bui-Thi-Thuy Q, Le-Thi-Minh H, Nguyen-Bao N, Le-Duc M, Ha-Thi P, Le-Quynh C, Nguyen-Thi-Phuong M, Ngo-Manh T, Bui-Ngoc L, Duong-Khanh T, Cao-Viet T, Tran-Minh D.   +16 more
europepmc   +1 more source

Sero-typing of human lymphocyte antigens: Preliminary trials on long-term kidney homograft survivors [PDF]

, 1965
Marchioro, TL, Starzl, TE, Terasaki, PI
core  

Humanised Mice in Cutaneous Leishmaniasis-T-Cell Recruitment Into Human Skin Transplants After Leishmania major Infection. [PDF]

Exp Dermatol
Miao L, Klapproth H, Stepkes MR, Wegner J, von Stebut E.   +4 more
europepmc   +1 more source

Optimizing biophysical properties of cellular niches to enhance stem cell‐derived extracellular vesicle function in musculoskeletal regeneration

BMEMat, EarlyView.
Extracellular vesicles (EVs) derived from stem cells show promise for applications in regenerative medicine, but their scalability and yield remain challenges. This review explores the approaches for biophysical modulations within cell niches on EV properties, discusses the current clinical application of EVs, and provides an outlook on the existing ...
Yang Xu, Chung Yin Matthew Cheung, Liling Liu, Hoi Pan Harry Cheung, Kam Yu Tam, Dai Fei Elmer Ker, Sarah H. Cartmell, Chuanbin Mao, Zhiyong Zhang, Dan Michelle Wang   +9 more
wiley   +1 more source

GlyT1 inhibition by ALX-5407 attenuates allograft rejection through suppression of Th1 cell differentiation. [PDF]

Front Immunol
Zhang X, Zhang W, Wei J, Jin S, Wang Z, Wang H, Feng G, Zhao J.   +7 more
europepmc   +1 more source